Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G




Comment for Type of Reporting Person:  Based on 21,035,930 shares of Common Stock outstanding as of August 5, 2026, consisting of (i) 16,274,026 shares of Common Stock outstanding as of July 28, 2026, as reported by Grace Therapeutics, Inc. in its 2026 proxy statement, and (ii) 4,761,904 shares of Common Stock issued by Grace Therapeutics, Inc. in a private placement on August 4, 2026, in which Opaleye, L.P. participated.


SCHEDULE 13G





SCHEDULE 13G



 
Opaleye Management Inc.
 
Signature:/s/ James Silverman
Name/Title:President
Date:08/07/2026
 
Opaleye, L.P.
 
Signature:/s/ James Silverman
Name/Title:General Partner
Date:08/07/2026
 
James Silverman
 
Signature:/s/ James Silverman
Name/Title:Individually
Date:08/07/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement by and among the reporting persons